Compass is still being developed and is effectively in beta. Some content and features may be incomplete, change, or not work as expected.

Content is anchored to trusted sources where available, but Compass has not yet been clinically reviewed. It provides general information rather than medical advice.

Feedback helps us identify gaps, errors, usability problems and opportunities to improve Compass over time.

How Compass is developedGive feedback

ALS Untangled does not support widespread use of antimycobacterial antibiotics for ALS

Original source

Anti-Mycobacterial AntibioticsALSUntangled · 3 August 2022 (opens in a new tab)

ALS Untangled says evidence linking MAP with amyotrophic lateral sclerosis (ALS) is not clear enough to support widespread use of antimycobacterial antibiotics. It says chest imaging could be reasonable for people with ALS who have atypical features such as pain, fevers or abnormal eye movements. More specific mycobacterial testing may be considered if imaging is abnormal.

Why this matters

This may help clinicians identify when further investigation could be considered in people with ALS whose symptoms are atypical. It does not establish that MAP causes ALS or that antimycobacterial antibiotics improve ALS, and it does not change treatment recommendations for most people with ALS.

Limitations and context

The review relies on a theorized association and two published case reports involving ALS-like conditions with atypical features. ALS Untangled describes the evidence as insufficient and notes that these antibiotics can be potentially toxic. The source is an independent expert review, not a clinical trial demonstrating treatment benefit.

Summarised by Compass 9 August 2026

This summary was generated by AI from the source listed above. It is not medical advice, so read the original source for anything that affects your care.

Relevant to you?